BioRelix, Inc.

5 Science Park
New Haven, CT 06511
203.785.9282
www.biorelix.com

BioRelix is developing antibiotics using a new riboswitch-based drug discovery platform. Riboswitches are short stretches of messenger RNA (mRNA) that bind small molecules and control genes that are essential for the survival of many human pathogens. First identified in the laboratory of Prof. Ron Breaker at Yale University, several different classes of riboswitch mRNAs have been identified and each potentially could serve as a novel anti-infective drug target.